{"filings":[{"id":972876,"accession_number":"0001193125-26-265835","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2026-06-10T20:11:13+00:00","items":["5.07"],"status":"ready","headline":"Prelude Therapeutics annual meeting: all director nominees elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Krishna Vaddi, Paul Scherer, Katina Dorton as Class III directors with over 26.9M shares for each.","Ratified Ernst & Young LLP as independent auditor for FY2026 with 31,841,080 shares for, 4,951 against.","Advisory vote to approve 2025 named executive officer compensation passed with 26,869,142 shares for.","Stockholders selected '1 Year' as frequency for future say-on-pay votes with 26,877,941 votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22321,"accession_number":"0001193125-26-218162","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2026-05-12T11:11:58+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prelude Therapeutics Q1 net loss $10.4M ($0.13/sh); cash runway into Q2 2028 after $90M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.4M ($0.13 per share) vs $32.1M ($0.42) in Q1 2025; R&D spend fell to $13.6M.","Cash, equivalents & securities of $84.8M at March 31; subsequent $90M offering extends runway to Q2 2028.","Initiated Phase 1 trial of PRT12396, mutant-selective JAK2V617F inhibitor, in PV and MF patients.","IND for KAT6A degrader PRT13722 expected by mid-2026; Phase 1 in ER+ breast cancer in 2H 2026.","Appointed Charles Morris, M.D. as Chief Medical Officer in April 2026."],"consensus_eps_estimate":-0.2533,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":4580000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94630,"accession_number":"0001193125-26-164510","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Prelude Therapeutics prices $90M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 18,018,014 common shares at $4.44/share and pre-funded warrants for 2,252,252 shares at $4.4399.","Gross proceeds ~$90M; net proceeds ~$85.5M after expenses.","Led by RA Capital Management and Soleus Capital; closes April 21, 2026.","Proceeds to fund R&D, working capital; extends cash runway into Q2 2028.","Underwriters: Goldman Sachs, Evercore ISI, Citizens Capital Markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94629,"accession_number":"0001193125-26-162620","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Prelude Therapeutics presents preclinical data for PRT13722 KAT6A degrader at AACR 2026, plans IND mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PRT13722 is a first-in-class, orally bioavailable, potent and highly selective KAT6A degrader for HR+/HER2- breast cancer.","Preclinical data show durable complete tumor regressions in xenograft models at well-tolerated doses as monotherapy.","PRT13722 demonstrated improved preclinical hematological safety profile compared to prifetrastat.","PRT13722 showed synergistic activity with endocrine therapy, CDK4/6 inhibitors, and PI3Kα inhibitors.","IND filing expected in mid-2026; Phase 1 study initiation planned for second half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94628,"accession_number":"0001193125-26-155978","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Prelude Therapeutics appoints Dr. Charles Q. Morris as Chief Medical Officer effective April 20, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Morris, age 61, brings over 30 years of oncology drug development experience; most recently CMO at Lava Therapeutics.","Annual base salary of $535,000, target bonus of 40% of base, and option for 450,000 PRLD shares vesting over 4 years.","Severance provides 9 months salary/benefits (or 12 months plus full bonus and equity acceleration in change-of-control context).","Company highlights his role will be critical as lead programs in MPN and ER+ breast cancer enter clinical development in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107145,"accession_number":"0001193125-26-104204","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prelude Therapeutics files $25M ATM equity offering via Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to sell up to $25M common stock under existing Sales Agreement with Jefferies LLC.","Offering supplements prior $75M capacity; shares sold from time to time at market prices.","Legal opinion from Morgan, Lewis & Bockius LLP filed as Exhibit 5.1.","Proceeds intended for general corporate purposes; no specific use disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107144,"accession_number":"0001193125-26-099424","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prelude Therapeutics FY2025 net loss narrows to $99.5M; cash $106.4M; IND cleared for PRT12396","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $99.5M ($1.29/share) improved from $127.2M ($1.68/share) in 2024.","Cash, equivalents and marketable securities $106.4M as of Dec 31, 2025; runway into Q2 2027.","FDA cleared IND for PRT12396 (mutant-selective JAK2V617F inhibitor); Phase 1 start expected Q2 2026.","KAT6A degrader PRT13722 IND filing planned mid-2026; Phase 1 initiation in H2 2026.","Exclusive option agreement with Incyte for JAK2 program (Nov 2025); DAC collaboration with AbCellera expanded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107143,"accession_number":"0001193125-26-034564","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA clears IND for Prelude's JAK2V617F inhibitor PRT12396; Phase 1 to start by Q2 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for PRT12396, a mutant-selective JAK2V617F inhibitor for myeloproliferative neoplasms.","Phase 1 study in polycythemia vera and myelofibrosis to initiate by Q2 2026.","PRT12396 is subject to an exclusive option agreement with Incyte (announced Nov 2025).","JAK2V617F mutation drives ~95% of PV, 60% of ET, and 55% of MF cases.","Open-label Phase 1 will assess safety, efficacy, and PK profile."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107142,"accession_number":"0001193125-26-008280","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Prelude Therapeutics furnishes investor presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an investor presentation dated January 2026 for use in investor meetings starting Jan 9.","The presentation includes forward-looking statements and general corporate overview.","No specific new clinical data, financial results, or corporate milestones were released.","The filing is a routine Regulation FD disclosure; presentation content not provided in full detail."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123484,"accession_number":"0001193125-25-275871","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prelude Q3 net loss $19.7M; cash into 2027; JAK2/KAT6A IND timelines set","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $19.7M ($0.26/sh) vs $32.3M ($0.43) YoY; cash $58.2M at Sep 30.","Received $60M upfront from Incyte for exclusive option on JAK2V617F inhibitor; cash runway into 2027.","JAK2V617F JH2 inhibitor IND filing expected Q1 2026; oral KAT6A degrader IND mid-2026.","Preclinical data for JAK2 inhibitor and mCALR DAC accepted for oral ASH Dec 2025 presentations.","Expanded AbCellera collaboration; additional license payment received in Oct 2025."],"consensus_eps_estimate":-0.3726,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":6500000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123483,"accession_number":"0000929638-25-004115","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Prelude gets $60M from Incyte for JAK2V617F option; pauses SMARCA2; CMO resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Incyte receives exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program for $100M exercise price, plus up to $775M milestones and single-digit royalties.","Prelude receives $60M in capital: $35M upfront plus $25M equity investment (6.25M shares at $4.00 each).","Company pauses clinical development of SMARCA2 degrader program to prioritize JAK2V617F and KAT6A degrader programs.","President and CMO Jane Huang resigns; board member Dr. Victor Sandor steps in to oversee clinical development.","Cash runway extended into 2027 (potentially 2028 if Incyte exercises option); preliminary cash ~$52M as of Oct 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123482,"accession_number":"0001193125-25-241968","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"Prelude Therapeutics appoints Katina Dorton to board; Mardi Dier resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mardi Dier resigned as Class III director effective Oct 17, 2025, not due to any disagreement.","Katina Dorton, J.D., MBA, appointed as Class III director and Audit Committee Chair, effective Oct 17.","Dorton brings 30+ years of healthcare finance and board experience; served as CFO at NodThera.","Dorton received option to purchase 76,000 shares vesting over 3 years under 2020 Equity Incentive Plan.","Dorton also serves on boards of Fulcrum Therapeutics (FULC) and TScan Therapeutics (TCRX)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140154,"accession_number":"0001193125-25-208187","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Prelude Therapeutics regains Nasdaq minimum bid price compliance as of Sept 18, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq non-compliance notice on March 27, 2025 for failing $1.00 bid price requirement.","On September 18, 2025, Nasdaq confirmed compliance with Listing Rule 5550(a)(2) and closed the matter.","Common stock (PRLD) remains listed on Nasdaq Global Select Market with bid price issue resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140153,"accession_number":"0000950170-25-108413","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prelude Therapeutics Q2 net loss $31.2M; pauses IV SMARCA2 degrader, focuses on oral PRT7732","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $31.2M ($0.41 per share) improved from $34.7M ($0.46) in Q2 2024.","Cash, equivalents and marketable securities $77.3M; runway into Q2 2026.","PRT3789 (IV) Phase 1 completed; will only advance with partnership. Oral PRT7732 enrolling 7th cohort (125 mg once daily); initial data by year-end 2025.","KAT6A degrader development candidate selected; IND on track for H1 2026.","R&D expense $25.8M (down from $29.5M); G&A $6.4M (down from $7.7M) YoY."],"consensus_eps_estimate":-0.4483,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157800,"accession_number":"0000950170-25-086170","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Prelude Therapeutics appoints new director from Baker Bros.; shareholders approve increase in authorized shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Paul Scherer, M.D. (Baker Bros. Advisors) as Class III director; granted options for 76,000 shares vesting over one year.","Stockholders elected Martin Babler and Victor Sandor as Class II directors for three-year terms at 2025 annual meeting.","Ratified Ernst & Young as independent auditor for fiscal year 2025 with 32,364,505 votes for, 132,459 against.","Approved amendment increasing authorized non-voting common stock from 12,850,259 to 112,850,259 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157799,"accession_number":"0000950170-25-064531","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prelude Q1 2025 net loss $32.1M; cash $103.1M funds ops into Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, restricted cash and marketable securities of $103.1M as of March 31, 2025.","Net loss of $32.1M ($0.42 per share) vs. $31.4M ($0.42) in Q1 2024; R&D expense $28.8M (+5% YoY).","PRT3789 monotherapy and docetaxel combo dose escalation complete; Phase 2 data expected H2 2025.","PRT7732 Phase 1 advancing in 5th cohort at 60 mg once daily; initial data anticipated H2 2025.","KAT6A degrader program targeting candidate nomination in Q2 2025 and IND in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157798,"accession_number":"0000950170-25-058776","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prelude Therapeutics presents preclinical data on SMARCA2 and KAT6A degraders at AACR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PRT3789, a selective SMARCA2 degrader in Phase 1/2, shows deep SMARCA2 degradation and high selectivity over SMARCA4.","KAT6A degraders demonstrate robust anti-cancer activity in preclinical breast and lung cancer models, including complete regressions.","Prelude's KAT6A degraders show reduced hematologic toxicity compared to dual KAT6A/B inhibitors, potentially improving safety.","SMARCA2 resynthesis rate is 2-3 times slower than SMARCA4, contributing to broad therapeutic index of PRT3789.","KAT6A degraders disrupt HAT complex and affect ERα expression, showing activity in ESR1- and PI3Kα-mutant and resistant cells."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176175,"accession_number":"0000950170-25-046839","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Prelude Therapeutics receives Nasdaq bid price deficiency notice; has until Sep 23, 2025 to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Prelude on March 27, 2025 that its common stock closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until September 23, 2025, to regain compliance by closing at $1.00 for 10 consecutive days.","If not compliant by Sep 23, Prelude may qualify for a second 180-day period if it meets other standards and intends a reverse stock split.","No immediate impact on listing; stock continues trading on Nasdaq under symbol PRLD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176174,"accession_number":"0000950170-25-035917","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prelude Therapeutics FY2024 net loss $127.2M; cash runway into Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $127.2M ($1.68/share) vs $121.8M ($2.02/share) in FY2023; R&D expense rose to $118.0M.","Cash, equivalents and marketable securities $133.6M at Dec 31, 2024; runway into Q2 2026.","PRT3789 showed 5 confirmed partial responses in NSCLC, gastric, esophageal cancer; safety acceptable.","PRT7732 oral SMARCA2 degrader Phase 1 enrollment ongoing; interim data expected H2 2025.","Bryant Lim named permanent CFO; company to seek partner for PRT2527 CDK9 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176173,"accession_number":"0000950170-25-014543","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Prelude Therapeutics appoints Bryant D. Lim as permanent CFO; base salary $483K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bryant D. Lim, previously interim CFO, appointed permanent CFO effective Feb 3, 2025; retains roles of Chief Legal Officer and Corporate Secretary.","Amended employment agreement provides base salary of $483,000, discretionary bonus up to 40% of base, and option for 200,000 shares vesting over 4 years.","Severance: nine months of base salary for termination without cause (non-change-of-control); twelve months for termination without cause or good reason related to change of control.","Option grant vests 25% on first anniversary and 1/48 monthly thereafter, subject to continued service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193069,"accession_number":"0000950170-24-135212","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prelude Therapeutics reports interim Phase 1 data for PRT2527; plans to partner CDK9 program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PRT2527 monotherapy ORR 17.4% (4/23 evaluable); combination with zanubrutinib ORR 38.5% (5/13 evaluable).","CRs observed in DLBCL (monotherapy and combo) and MCL (combo); responses in patients with prior CAR-T therapy.","Most common TEAE: neutropenia (48%, grade≥3: 46%); one DLT of tumor lysis syndrome at 24 mg/m2 dose.","Prelude will seek a partner for PRT2527 to focus resources on SMARCA degrader programs.","Data presented at 66th ASH Annual Meeting on Dec 11, 2024; 46 patients safety-evaluable as of Sep 17, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193068,"accession_number":"0000950170-24-122337","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prelude Therapeutics Q3 net loss $32.3M; PRT3789 shows partial responses in SMARCA4-mutated cancers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $153.6M; net loss $32.3M ($0.43/share) vs $30.6M prior year.","PRT3789 Phase 1: 4 confirmed partial responses in 26 evaluable SMARCA4-mutated NSCLC/esophageal patients; combo with docetaxel safe.","Initiated Phase 1 trial of oral SMARCA2 degrader PRT7732 in biomarker-selected SMARCA4-mutated cancers.","PRT2527 interim Phase 1 data in hematological malignancies to be presented at ASH Dec 2024; dose escalation completing this year.","Entered collaboration with Pfizer Ignite for SMARCA2 degrader development; Prelude retains full ownership."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":3000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193067,"accession_number":"0000950170-24-116853","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prelude Therapeutics PRT3789 Phase 1 interim data: 4 PRs; DAC program preclinical proof-of-concept","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim Phase 1 results: 4 confirmed partial responses (2 esophageal, 2 NSCLC) out of 26 evaluable SMARCA4 loss-of-function patients.","PRT3789 generally well-tolerated; no dose-limiting toxicities or drug-related SAEs; higher doses (≥212 mg) show deeper SMARCA2 degradation.","Combination with docetaxel shows acceptable safety profile; preclinical data show synergy with chemo in SMARCA4-mutant NSCLC models.","First preclinical proof-of-concept for SMARCA2/4 dual degrader antibody conjugates (DACs): anti-PSMA DACs show efficacy and tolerability in xenograft models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209448,"accession_number":"0000950170-24-106362","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prelude reports Phase 1 interim data: PRT3789 shows 3 confirmed PRs in NSCLC/esophageal, well tolerated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3 confirmed partial responses in 2 esophageal and 1 NSCLC patient out of 26 evaluable; 7 patients had tumor shrinkage.","PRT3789 was well tolerated in 65 patients; no dose-limiting toxicities or drug-related serious adverse events.","Dose escalation continues to cohort 9 (500 mg once weekly); MTD not yet reached.","Company expects to confirm biologically active dose as monotherapy by year-end.","Data presented at ESMO 2024; also selected for plenary session at EORTC-NCI-AACR Symposium in October 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209447,"accession_number":"0000950170-24-104575","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Prelude Therapeutics Publishes Phase 1 Abstract for PRT3789 SMARCA2 Degrader at ESMO 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract details first clinical data for PRT3789, a first-in-class IV SMARCA2 degrader in SMARCA4-mutated advanced solid tumors.","As of March 7, 2024, 40 patients enrolled across 6 dose levels (24-212 mg); no DLTs or study-drug-related SAEs reported.","Dose-dependent decreases in SMARCA2 levels observed; RECIST partial responses and tumor shrinkage noted in heavily pretreated NSCLC and esophageal cancer.","Company will host investor webcast on September 13, 2024 at 12:00 PM EST following oral presentation at ESMO Congress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209446,"accession_number":"0000950170-24-095059","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prelude Therapeutics Q2 net loss $34.7M; cash $179.8M; clinical milestones for SMARCA2 and CDK9 programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $34.7M ($0.46/share) vs $30.4M ($0.54/share) in Q2 2023; R&D expense rose to $29.5M from $25.0M.","Cash, equivalents and marketable securities $179.8M at June 30, 2024; runway extended into 2026.","PRT3789 interim Phase 1 data selected for oral presentation at ESMO Congress 2024 (Sept 13).","IND authorized for oral SMARCA2 degrader PRT7732; Phase 1 start expected H2 2024.","Clinical collaboration with Merck to evaluate PRT3789 in combination with KEYTRUDA; Phase 2 start expected Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227478,"accession_number":"0000950170-24-074846","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Prelude Therapeutics stockholders elect two Class I directors, ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Paul A. Friedman, M.D. elected as Class I director with 31,165,370 votes for, 1,762,716 withheld.","David P. Bonita, M.D. elected as Class I director with 31,007,172 votes for, 1,920,914 withheld.","Ratification of Ernst & Young LLP as independent auditor for FY2024: 34,994,229 for, 57,512 against, 14,440 abstaining.","Broker non-votes of 2,138,095 on director elections; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227477,"accession_number":"0000950170-24-072249","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Prelude Therapeutics posts corporate presentation and SMARCA degrader educational series","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished a corporate presentation (Exhibit 99.1) dated June 2024.","Launched educational video series on SMARCA degraders available via investor website.","No financial results, clinical data, or material business changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227474,"accession_number":"0000950170-24-061079","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K/A","filed_at":"2024-05-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Prelude Therapeutics grants 25,000 stock options to Interim CFO Bryant D. Lim","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Options to purchase 25,000 shares of common stock at $3.86 per share.","Options vest over 4 years (25% at 1 year, then monthly); 10-year term.","Grant approved by Compensation Committee on May 14, 2024, under 2020 Equity Incentive Plan.","Amendment to prior 8-K reporting Lim's appointment as Interim CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227476,"accession_number":"0000950170-24-053931","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prelude Therapeutics Q1 net loss $31.4M; cash $201.9M; pipeline on track for H2 2024 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $31.4M ($0.42/diluted share) vs $27.7M ($0.58) in Q1 2023; R&D spend $27.4M up from $21.8M.","Cash, equivalents & marketable securities $201.9M as of March 31, 2024; cash runway expected into 2026.","PRT3789 (SMARCA2 degrader) and PRT2527 (CDK9 inhibitor) on track for initial proof-of-concept data H2 2024.","PRT7732 oral SMARCA2 degrader expected to enter Phase 1 in H2 2024; IND-enabling studies ongoing.","Appointed Sean Brusky as CBO and Robert Doody as SVP, IR in April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227475,"accession_number":"0000950170-24-043347","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Prelude Therapeutics CFO departs; Bryant Lim named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Laurent Chardonnet ceased as CFO on April 8, 2024; he will consult at $500/hr through Oct 4, 2024.","Bryant D. Lim, current Chief Legal Officer and Secretary, appointed interim CFO.","Chardonnet receives severance of $333,750 (9 months base salary) plus COBRA subsidy.","Consulting fee up to $50,000; Chardonnet's equity awards continue vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246330,"accession_number":"0000950170-24-015913","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prelude Therapeutics reports FY2023 net loss of $121.8M; cash runway into 2026, pipeline milestones set for 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $232.9M as of Dec 31, 2023, expected to fund operations into 2026.","Net loss $121.8M ($2.02/share) for FY2023 vs $115.4M ($2.44/share) for FY2022.","R&D expenses increased to $103.4M from $92.9M; G&A expenses decreased to $28.9M from $30.7M.","PRT3789 (SMARCA2 degrader) on track for monotherapy dose escalation mid-2024; combo with docetaxel initiated H1 2024.","PRT2527 (CDK9 inhibitor) to initiate combo with zanubrutinib Q1 2024; PRT7732 (oral SMARCA2 degrader) IND filing H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263766,"accession_number":"0000950170-23-069210","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Prelude Therapeutics raises $25M via pre-funded warrant private placement for SMARCA2 pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$25M from sale of 7,936,759 pre-funded warrants at $3.1499 each, exercise price $0.0001.","Net proceeds estimated at $24.9M after offering expenses.","Funds primarily support SMARCA2 portfolio: IV molecule PRT3789 clinical development and oral program IND.","Cash runway now expected into 2026; closing expected Dec 13, 2023.","Warrants are immediately exercisable, subject to 4.99% beneficial ownership cap (waivable to 19.99%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263765,"accession_number":"0000950170-23-057481","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prelude prioritizes SMARCA2 and CDK9, partners with AbCellera on ADCs, reports Q3 net loss $30.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $30.6M ($0.45/share); cash at $230.5M; cash runway into 2026.","Prioritizing PRT3789 (SMARCA2 degrader) and PRT2527 (CDK9 inhibitor) for continued development.","Discontinuation of MCL-1 (PRT1419) and CDK4/6 (PRT3645) programs; seeking partners for PRT3645.","Entered partnership with AbCellera to develop precision ADCs using SMARCA payloads.","Expects initial Phase 1 data for SMARCA2 and CDK9 in mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280977,"accession_number":"0001193125-23-202314","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prelude posts Q2 net loss $30.4M; cash $255M funds operations into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.4M ($0.54/share) vs $27.4M ($0.58/share) in Q2 2022.","R&D expense rose to $25.0M from $21.3M YoY; G&A fell to $7.4M from $8.2M.","Cash, equivalents and marketable securities $255.0M; completed public offering raising $113M gross.","Pipeline milestones: CDK9 (PRT2527) confirmation dose target Q1 2024; SMARCA2 degrader IND early 2024.","Management expects cash runway into 2026; four lead programs on track for data."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299656,"accession_number":"0001193125-23-171145","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Prelude Therapeutics shareholders elect two Class III directors, ratify auditor, approve charter amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Krishna Vaddi, Ph.D. and Mardi C. Dier elected as Class III directors with ~27M votes for each.","Ernst & Young LLP ratified as independent auditor for FY2023 with 28.78M for, 6,022 against.","Amendment to certificate of incorporation for officer exculpation passed with 22.71M for, 97,553 against.","All proposals passed; broker non-votes reported for director elections and charter amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299655,"accession_number":"0000950170-23-025712","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Prelude Therapeutics furnishes May 2023 investor presentation","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company prepared investor presentation materials for use in investor meetings.","Presentation provided as Exhibit 99.1, furnished under Regulation FD, not filed.","No specific financial or pipeline updates disclosed in the 8-K filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299654,"accession_number":"0001193125-23-149304","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Prelude Therapeutics prices $100M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3.05M voting shares and 1.45M non-voting shares at $5.75/share; pre-funded warrants for 12.9M shares at $5.7499 each.","Gross proceeds $100M, net proceeds ~$98.5M; underwriter Morgan Stanley; expected close May 22, 2023.","Proceeds to advance pipeline (PRT2527, PRT1419, PRT3645, PRT3789) and new SMARCA2 oral molecule R&D.","Underwriters granted 30-day option to purchase up to 2.6M additional shares of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299653,"accession_number":"0001193125-23-146980","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prelude Therapeutics files updated investor presentation; no material new data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed an updated corporate presentation dated May 2023 as Exhibit 99.1 to Form 8-K.","Presentation intended for use in investor meetings; contains no specific financial results or guidance changes.","No new business developments, clinical data, or strategic announcements included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299652,"accession_number":"0000950170-23-018477","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prelude Therapeutics Q1 2023 net loss $27.7M; cash runway unchanged into Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $27.7M ($0.58 loss per share) vs $29.5M ($0.63) in Q1 2022.","Cash, cash equivalents & marketable securities $172.3M; funding operations into Q4 2024.","R&D expenses decreased to $21.8M from $22.8M YoY.","PRT2527 CDK9 inhibitor solid tumor dose escalation complete; RP2D in hematological malignancies expected 2H 2023.","Phase 1 dose escalation of PRT3789 (SMARCA2 degrader) ongoing; oral candidate nomination expected early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319772,"accession_number":"0001193125-23-071400","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Prelude Therapeutics enters $75M at-the-market stock offering agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered Open Market Sale Agreement with Jefferies LLC to sell up to $75M of common stock.","Sales will be made 'at the market' under existing shelf registration statement (File No. 333-261019).","Jefferies receives up to 3.0% commission on gross proceeds; company not obligated to sell any shares.","Agreement terminates upon sale of all shares or earlier termination by either party.","Proceeds intended for general corporate purposes and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319771,"accession_number":"0000950170-23-007983","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Prelude Therapeutics reports FY 2022 net loss of $115.4M; cash runway through Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $115.4M ($2.44 per share) vs $111.7M ($2.43 per share) in FY 2021.","Cash and equivalents of $201.7M as of Dec 31, 2022; runway extended through Q4 2024.","R&D expenses $92.9M, G&A $30.7M; both up YoY.","Clinical trial collaboration with BeiGene to evaluate PRT2527 + zanubrutinib in hematologic malignancies.","Bryant D. Lim appointed Chief Legal Officer, effective Feb 20, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319770,"accession_number":"0000950170-23-002729","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Prelude Therapeutics posts investor presentation for SVB Global Biopharma Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed investor presentation under Regulation FD for Feb 2023 SVB conference.","Presentation attached as Exhibit 99.1 with no specific financial or clinical details in filing body.","No new material events, guidance changes, or operational updates disclosed in the 8-K text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319769,"accession_number":"0000950170-23-001023","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2023-01-23T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Prelude Therapeutics amends bylaws for universal proxy rules and DGCL updates","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended bylaws effective Jan 19, 2023, addressing SEC universal proxy rules (Rule 14a-19) and recent DGCL amendments.","Revised advance notice provisions require additional disclosures, limit nominees to board seats available, and mandate nominee interviews.","New rule requiring universal proxy solicitors to use non-white proxy cards; stockholders must certify compliance with Rule 14a-19.","Added emergency bylaw provision for board/quorum during crises; updated electronic notice procedures.","Updates to stockholder meeting conduct, including attendance procedures and Rule 14a-8 proponent rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319768,"accession_number":"0000950170-23-000439","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Prelude Therapeutics files corporate presentation; no specific new details provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Prelude Therapeutics made a corporate presentation available to investors on January 9, 2023.","The presentation was furnished under Regulation FD but its substantive content was not disclosed.","No changes to revenue, EPS, pipeline status, or corporate strategy were announced.","The filing does not contain any new material information beyond the existence of the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337981,"accession_number":"0000950170-22-024727","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prelude Q3 net loss $30.0M; FDA clears two INDs, halts PRMT5 internal development","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.0M ($0.63 per share) vs $30.7M ($0.66) in Q3 2021.","Cash, equivalents & marketable securities $224.0M; runway into Q4 2024.","FDA cleared INDs for PRT3789 (SMARCA2 degrader) and PRT3645 (brain-penetrant CDK4/6 inhibitor).","Discontinues internal PRMT5 program (PRT543, PRT811) to focus on higher-potential assets.","PRT2527 CDK9 Phase 1 dose escalation on track for RP2D by year-end; no dose reduction AEs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355341,"accession_number":"0001564590-22-028595","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prelude Therapeutics Q2 2022 net loss $27.4M; cash $246.3M; IND accepted for CDK4/6 inhibitor PRT3645","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $27.4M ($0.58/share) vs $26.9M ($0.58/share) Q2 2021; R&D declined $1.1M to $21.3M.","Cash, equivalents, and marketable securities $246.3M as of June 30, 2022; funds operations into H2 2024.","FDA accepted IND for brain-penetrant CDK4/6 inhibitor PRT3645; Phase 1 to begin Q4 2022 in multiple cancers.","PRMT5 (PRT811) expansion cohort data readout and next steps expected H2 2022; MCL1 combo data by end of 2022.","SMARCA2/BRM degrader program on track to file IND by year-end 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373476,"accession_number":"0001564590-22-023674","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Prelude Therapeutics stockholders elect three Class II directors and ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Martin Babler elected with 27,034,110 votes for; 54,875 withheld; 1,215,046 broker non-votes.","Julian Baker elected with 25,635,979 votes for; 1,453,006 withheld; 1,215,046 broker non-votes.","Victor Sandor elected with 26,057,360 votes for; 1,031,625 withheld; 1,215,046 broker non-votes.","Ernst & Young ratified as independent auditor for FY2022: 28,293,151 for, 5,385 against, 5,495 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373475,"accession_number":"0001564590-22-019084","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prelude Q1 net loss $29.5M ($0.63/sh); cash $266.2M funds into 2H2024; on track for data readouts in 2H2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.5M ($0.63/sh) vs $21.3M ($0.47) YoY; R&D expense $22.8M ($16.5M) on increased clinical activity.","Cash & equivalents $266.2M as of March 31, 2022, expected to fund operations into second half 2024.","PRMT5 program (PRT811) expansion cohort data analysis ongoing; next steps decision in 2H2022.","MCL1 inhibitor PRT1419 IV formulation prioritized; combination cohorts expected by mid-2022.","Jane Huang appointed President and CMO effective April 4, 2022; previously CMO Hematology at BeiGene."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373474,"accession_number":"0001193125-22-100388","cik":1678660,"company_name":"Prelude Therapeutics Inc","ticker":"PRLD","form_type":"8-K","filed_at":"2022-04-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Prelude Therapeutics EVP/Chief of Clinical Affairs Morosini resigns; advisor through May 5","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deborah Morosini resigned as EVP and Chief of Clinical Affairs effective April 6, 2022.","She will serve as Strategic Advisor to the President until May 5, 2022, then employment ends.","Severance includes 3 months base salary and 3 months COBRA premium payments.","She may provide consulting services from May 5 to November 4, 2022 on an as-needed basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":325749307.47836536,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-04-08T23:59:59+00:00|373474"}